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A novel disorder reveals clathrin heavy chain-22
is essential for human pain and touch
development
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Congenital inability to feel pain is very rare but the identiﬁcation of causative genes has yielded signiﬁcant insights into pain
pathways and also novel targets for pain treatment. We report a novel recessive disorder characterized by congenital insensitivity to
pain, inability to feel touch, and cognitive delay. Affected individuals harboured a homozygous missense mutation in CLTCL1
encoding the CHC22 clathrin heavy chain, p.E330K, which we demonstrate to have a functional effect on the protein. We found
that CLTCL1 is signiﬁcantly upregulated in the developing human brain, displaying an expression pattern suggestive of an early
neurodevelopmental role. Guided by the disease phenotype, we investigated the role of CHC22 in two human neural crest
differentiation systems; human induced pluripotent stem cell-derived nociceptors and TRKB-dependant SH-SY5Y cells. In both
there was a signiﬁcant downregulation of CHC22 upon the onset of neural differentiation. Furthermore, knockdown of CHC22
induced neurite outgrowth in neural precursor cells, which was rescued by stable overexpression of small interfering RNA-resistant
CHC22, but not by mutant CHC22. Similarly, overexpression of wild-type, but not mutant, CHC22 blocked neurite outgrowth in
cells treated with retinoic acid. These results reveal an essential and non-redundant role for CHC22 in neural crest development
and in the genesis of pain and touch sensing neurons.
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Pain and touch are amongst the ubiquitous senses of com-
plex multi-cellular organisms. For sight and hearing, muta-
tions in 5200 human genes are known to cause congenital
blindness or deafness, respectively (Dror and Avraham,
2009; Daiger et al., 2013). Study of these genes has sub-
stantially contributed to our understanding of development
of these sensing systems. Far fewer genes have been dis-
covered that cause a loss of pain sensing (Cox et al.,
2006; Rotthier et al., 2012; Leipold et al., 2013).
However, the discovery of such genes is leading to treat-
ments for individuals suffering from excess and unwanted
pain—not a situation analogous to other senses (Holmes,
2012).
Pain is a complex sense, essential for detecting or warn-
ing of impending tissue damage and capable of detecting
noxious stimuli of diverse origins and forms. Specialist
nociceptors are of neuronal origin, and are the primary
detectors of such insults. Mendelian disorders of painless-
ness, deﬁned by the discovery of pathogenic mutations, can
be clinically classiﬁed as developmental (a failure of noci-
ceptor differentiation), dysfunctional (unresponsive noci-
ceptors), and degenerative (where nociceptors prematurely
die) (Cox et al., 2006; Rotthier et al., 2012; Leipold et al.,
2013). We have identiﬁed a novel Mendelian disorder char-
acterized by a congenital insensitivity to pain, loss of touch
sensation and severe cognitive delay, which clearly ﬁts into
the developmental category and hence deﬁnes a hitherto





Autozygosity mapping was undertaken using samples from the
affected children as previously reported (Woods et al., 2006b).
In brief, genomic DNA from each affected individual was
hybridized to the Affymetrix GeneChip

Human Mapping
250K Nsp Array. Results of the alleles present at each SNP
for each individual were generated using Affymetrix software.
Regions of shared allele-concordant homozygosity were sought
using ExcludeAR (Woods et al., 2004). We found ﬁve statis-
tically signiﬁcant shared allele-concordant homozygosity re-
gions; chromosome 5:157–161 cM, chromosome 9:121–133
cM, chromosome 16:72–76 cM, chromosome 20:31–50 cM,
and chromosome 22:17–26 cM. The ﬁnding of ﬁve shared
homozygous regions encompassing 1.5% of the genome was
within the expected result range given the consanguineous
family structure (Woods et al., 2006a). Analysis of the
exome sequencing results detailed in the next section con-
ﬁrmed all of the homozygous regions identiﬁed, as the major-
ity of contained DNA changes (490% averaged over the ﬁve
regions) were homozygous.
Exome sequencing
Exome sequencing performed on one affected child was under-
taken using the SureSelect Human All Exon 50Mb Kit
(Agilent Technologies UK, Cat. No G3370A), enabling tar-
geted capture of 50Mb sequence of exonic regions and non-
coding RNAs in the human genome. Sequencing was per-
formed with the SOLiD
TM
4 System (Applied Biosystems) with
50 bp fragment reads, to generate 4.3Gb of sequence achieving
83% of bases coverage by 410 reads (sufﬁcient for the detec-
tion of homozygous mutations) of the mappable targeted
50Mb exome. Initially, the raw sequencing reads were
mapped to the GRCh37 reference human genome and changes
compared to this reference sequence identiﬁed (Bochukova
et al., 2012). We focused our analyses on non-synonymous
coding, nonsense, splice site variants, and indels (insertions–
deletions) involving exons. We ﬁltered against: (i) known vari-
ations where the rare allele frequency was 41% (derived from
dbSNP and 1000 Genomes); (ii) evolutionary conservation of
the encoded amino acid, by use of the Human Genome
Browser; and (iii) examination of the sequence reads contain-
ing potential mutations using the Integrated Genome Viewer
(which shows misaligned, poorly sequenced and recurrent arte-
fact changes). We did not ﬁlter on either the known function
of recessive mutations in a variant-containing gene or on ex-
pression pattern. These ﬁltering steps resulted in the reduction
of 19 to only one potentially pathogenic variant in the con-
cordant homozygous regions found in all affected children,
c.988G4A in CLTCL1 (p.E330K in CHC22). No further mu-
tations in CLTCL1 were found in a cohort of 39 painless
patients of unknown genetic cause
Segregation analysis and control subject analysis
PCRs were designed to cover the region of CLTCL1 contain-
ing the c.988G4A mutation, which was within exon 7. For
this we used the Human Genome Browser and Primer3Web,
and optimized the reaction in control human genomic DNA.
Using genomic DNA samples from family members we found
that the mutation was homozygous in all affected children,
heterozygous in both parents, and heterozygous in the one
unaffected sibling we could test. Using the same primers we
analysed genomic DNA from a personally curated resource of
50 Arab and 130 Pakistani healthy adults. All were homozy-
gous for the wild-type G allele of the mutation c.988G4A.
The mutation was not present in the 1000 Genomes project.
Details of websites and software used can be found in
Appendix 1.
Cell lines and culture conditions
SH-SY5Y cells were purchased from Sigma Aldrich, and were
cultured in 100% Dulbecco’s modiﬁed Eagle medium
(DMEM) supplemented with 10% foetal bovine serum, 100
U/ml penicillin-streptomycin (pen-strep) at 37C and 5%
CO2. HEK293 cells were maintained in 100% DMEM simi-
larly supplemented. To achieve transient transfection of
HEK293 cells, cells were plated into six-well plates at
2  105 cells/well 24 h before transfection. Transfection was
achieved using the TransIT

-LT1 transfection reagent
(Mirusbio) according to the manufacturer’s protocol. After
72 h the cells were harvested or ﬁxed for western blot analysis
or immunoﬂuorescence analysis, respectively (see below).
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To create stably expressing clones, cells were transfected as
described for transient transfection. After 48 h, the cells were
trypsinized and transferred to a 100mm dish. After a further
24 h the media was changed for one containing 600 mg/ml
G418 sulphate solution (Calbiochem). Once stably expressing
colonies had formed, these were picked using cloning cylinders
and successfully transfected clones determined by immuno-
ﬂuorescence and western blotting. Two successfully transfected
CHC22.E330K clones were created, with all cells exhibiting a
GFP signal by immunoﬂuorescence and of the correct size
determined by western blotting. However, wild-type clones
proved harder to produce, with the best expressing clone
(out of a further 20) being used for further experiments.
This clone expressed comparable amounts of GFP per cell
compared with the p.E330K expressing cells, but was not a
pure population with a varying proportion of cells not express-
ing GFP (depending on passage number). These cells were rou-
tinely sorted for GFP-expressing cells before experimentation,
but a totally pure population was not achieved. When these
cells were subsequently analysed, only those cells expressing
GFP were included in the analysis.
Transfection of siRNA was achieved using INTERFERin

in vitro small interfering RNA (siRNA) transfection reagent
(Polyplus) using a reverse transfection according to the manu-
facturer’s protocol. Brieﬂy, cells were plated on Day 0 at
1.5  104 cells/ml onto a mixture of 15 nM siRNA diluted in
200ml Opti-MEM

media and 12 ml INTERFERin

reagent.
Media was replaced on Day 3 with more of the same siRNA
mixture added to the cells as on Day 0. Cells were imaged and
assayed on Day 5. The methods for differentiating pain neu-
rons from human pluripotent stem cells have been described
previously (Chambers et al., 2012).
Differentiation of SH-SY5Y cells has been described previ-
ously (Encinas et al., 2000). Brieﬂy, cells were plated at
1.5  104 cells/ml. The following day media was changed for
that containing 10 mM retinoic acid (or equal volume DMSO
as control) and left for 5 days. Media was changed to fresh
media containing retinoic acid on the third day. Cells were
assayed at Day 5 after signiﬁcant neurite outgrowth had
occurred, but cells remained mitotic.
DNA constructs, antibodies and RNA
interference
Small interfering RNAs were purchased from Life
Technologies or Qiagen. The siRNAs against CHC22 were
GGCYCAAUCGUGAACUUCAtt (siCHC22.1) and GAAGA
UGUUUGAUGACAUtt (siCHC22.2), CHC17 were CGUUG
CUCUUGUUACGGAUtt (siCHC17.1) and GGGAAUUC
UUCGUACUCCAtt (siCHC17.2) and scrambled was UUC
UCCGAACGUGUCACGUtt.
Primary antibodies used include Human Clathrin Heavy
Chain 2/CHC22 Polyclonal Sheep IgG Antibody (R&D
Systems), Human Clathrin Heavy Chain 1/CHC17 Afﬁnity
Puriﬁed PAb (R&D Systems) (antibodies were proven not to
cross-react with either endogenous or over-expressed protein;
see Supplementary Fig. 2), Trk (pan) C17F1 Rabbit mAb 4609
(Cell Signalling Technology), anti-TrkB Mouse mAb 610101
(BD Transduction Laboratories), GFP (D5.1) XP Rabbit mAb
#2956 (Cell Signalling Technology), anti-beta Actin (AC-15)
antibody (ab6276) (Abcam).
DNA constructs used are detailed in Fig. 2. DNA plasmids
used to simultaneously knockdown endogenous CHC17 by
RNA interference and to express GFP-tagged CHC22.WT or
CHC22E330K under a CMV promoter, called ‘pBrain con-
structs’ have been described previously (constructs iii, iv, v),
as have plasmids to expressed GFP-tagged CHC22 with no
knockdown (construct i) (Royle et al., 2005). The p.E330K
mutation was introduced into plasmids i and v using the
QuikChange

II Site-Directed Mutagenesis Kit (Agilent
Technologies) according to the manufacturer’s protocol, and
successful plasmids conﬁrmed by DNA sequencing (constructs
ii and vi). Human CHC17 was knocked down using construct
iv, which was otherwise the same as constructs v and vi, but
did not express a protein fused to its GFP. Construct iii con-
tained short hairpin (sh)RNA, was targeted against rat clathrin
heavy chain and was unable to knockdown expression of
human CHC17.
For making stably overexpressing SH-SY5Y cells, the
GFP-tagged constructs i and ii described above were
mutated to make them resistant to siCHC22.2 using the Site-
Directed Mutagenesis Kit (Agilent Technologies). To achieve
this, two site-directed mutagenesis reactions were set up to in-
duce 4-bp changes that had no impact on the amino acids
translated. The ﬁnal sequence of the siRNA target region
was as follows CTCCCAGCCCATGAAAATGTTCGACCGA
CATACCAGTCTG (bold and underlined represent mutated
bases).
Transferrin internalization assay
HEK293 cells plated onto poly-L-lysine-coated glass coverslips,
were transfected as above with constructs which knock down
endogenous CHC17 and re-express CHC22.WT or
CHC22.E330K simultaneously (constructs v and vi). As a con-
trol for effective shRNA against CHC17 blocking transferrin
internalization, constructs iii and iv were also transfected. On
the third day after transfection, the cells were starved of serum
for 35min to deplete the cells of transferrin. The cells were
then incubated with DMEM containing 100 mg/ml of Alexa
Fluor

568-conjugated transferrin (Life Technologies) at
37C for 10min. Cells were then washed, ﬁxed in 4% paraf-
ormaldehyde and mounted onto ProLong

Gold antifade re-
agent with DAPI (Life Technologies). Cells were visualized
with either a LSM510 or a LSM710 confocal microscope.
For quantitative experiments, identical laser power and acqui-
sition settings were used. For analysis of transferrin uptake,
images were thresholded using ImageJ (NIH) software, the
outline of each cell (using the green signal traced) around
and the integrated density of the red signal (transferrin) calcu-
lated. Experiments testing the rescue of CHC17 depletion by
either CHC22.WT or CHC22.E330K were carried out four
independent times, with at least 136 and 153 cells counted
for each condition, respectively. Experiments to conﬁrm
knockdown of CHC17 (using comparison of constructs iii
and iv) caused signiﬁcant reduction in transferrin uptake (pre-
viously conﬁrmed by Hood and Royle, 2009; Willox and
Royle, 2012) were carried out twice, with at least 58 cells
counted for each condition.
Co-localization was measured by Pearson Co-localization
Coefﬁcient using Volocity Image analysis software.
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Producing heat maps from
developmental transcriptome
The raw log2 transformed expression values (reads per kilo-
base of exon model per million mapped reads) of CLTCL1
and CLTC extracted from various brain regions across devel-
opment from embryo to mature adult brain, were downloaded
from the ‘Brainspan Atlas of the Developing Human Brain’
(Website: 2014 Allen Institute for Brain Science. BrainSpan
Atlas of the Developing Human Brain [Internet]. Available
from: http://brainspan.org/) (Miller et al., 2014). These
values were imported into Microsoft Excel and ordered ac-
cording to developmental stage (time points with insufﬁcient
data were excluded from analysis at this stage). Where there
were multiple samples for each developmental stage, an aver-
age expression value was calculated. Then, for each respective
brain region, the expression values were calculated as a pro-
portion of the largest expression value for that region (largest
value 1) and a heat map produced with darker red colour
assigned to values closest to 1 and dark blue representing
the lowest expression value for that brain region. Hence, the
heat map represents a spread of the highest to lowest expres-
sion of each given gene across development for each brain
region, but the different regions themselves are not directly
comparable with each other, nor can the colours for
CLTCL1 be compared directly to CLTC. The donor
H376.VIII.53 for the 2-year time point was excluded from
the analysis because for both CLTCL1 and CLTC it repre-
sented a signiﬁcantly outlying result, likely to represent an
unknown issue with the donor or sample preparation and
not to represent a genuine transcriptional level of either gene
at this time point.
Previous studies have shown that CLTC is expressed at
greatly increased amounts compared to CLTCL1, and so we
sought to analyse the comparative amounts of the two genes
throughout CNS development. The analysis described above
allowed us to demonstrate the relative changes in the expres-
sion levels of the two genes over development, but not directly
compare the two clathrins. To compare the levels of CLTCL1
to CLTC directly we calculated the percentage of overall cla-
thrin heavy chain expression represented by CLTCL1 and
CLTC, respectively. To achieve this, the log2 transformed
expression values originally downloaded were reverse log
transformed to comparative transcription values. The expres-
sion of CLTCL1 expression as a percentage of total clathrin
levels was calculated for each time point (percentage of
CLTCL1 expression compared to CLTCL1 + CLTC expres-
sion), and the data split into either pre- or postnatal. The
pre- and postnatal groups were then compared using
Students t-test.
Neurite outgrowth assays
SH-SY5Y cells were transfected with siRNA, as described
above, and left for 5 days (change of media and second hit
of siRNA added on Day 3). This time point was selected be-
cause a clear distinction in cell phenotype was apparent (Days
4 and 6 were also tested with comparable results), and knock-
down was optimal. For each experiment, at least three ﬁelds of
view were imaged for phase contrast images using an EVOS
FLCell Imaging System and for phase contrast plus green
signal for stably expressing cells. The images were blinded
and neurite outgrowth measured using ImageJ software. For
‘neurite length per cell’ measurements, all neurites, however
small, were measured and the total neurite length of all cells
combined, divided by the number of cells in that ﬁeld of view.
For ‘percentage of cells bearing neurites’, the same data were
analysed, but the number of ‘neurites’ taken as only neurites




Bovine clathrin heavy chain terminal domain plasmid (residues
1–363) has been described previously (Miele et al., 2004). The
p.E330K mutation was introduced into the sequence using
QuikChange

II Site-Directed Mutagenesis Kit (Agilent
Technologies). Both wild-type and mutant plasmids were pre-
pared as previously described to produce protein with an N-
terminal GST (glutathione S-transferase) tag (Drake and
Traub, 2001). Brieﬂy, the GST fusion proteins were produced
in Escherichia coli BL21 DE3 plysS cells. Log-phase cultures
(A600 0.8) growing at 37C were placed at 22C in a shak-
ing incubator and induced to produce protein by addition of
isopropyl-1-thio-b-D-galactopyranoside (IPTG) to a ﬁnal con-
centration of 100mM, and left overnight. The bacteria were
then recovered by centrifugation at 4500 rpm at 4C for
15min and the cell pellets frozen at 80C. GST fusions
were collected on glutathione Sepharose 4B after lysis of the
bacteria, and cleaved from the GST with thrombin. After ex-
tensive washing, lysates were eluted from the beads and the
thrombin inactivated with ABESF [4-(2-aminoethyl)
benzenesulphonyl ﬂuoride hydrochloride]. Proteins were con-
centrated to 10mg/ml and puriﬁed by gel ﬁltration on an
analytical S200 column (GE healthcare) in 200mM
NaCl, 10mM HEPES pH 7.5, 1mM dithiothreitol. Samples
for circular dichroism at 0.5mg/ml were dialysed into 50mM
Na phosphate pH 7.5.
Protein extraction
Cells were grown in six-well plates, washed with phosphate-
buffered saline (PBS) and scraped in RIPA buffer (Tris, pH 7.4,
NaCl 150mM, EDTA, 0.5mM, 1% Triton), containing pro-
tease inhibitors (Roche Applied Sciences). Lysates were cleared
by centrifugation at (12 000 rpm at 4C for 20min) and levels
of total cellular protein tested using the DC
TM
protein assay kit
according to manufacturer’s instructions (Bio-Rad).
Protein blotting
Fifteen to twenty-ﬁve micrograms of extracted total cellular
protein were separated using either 8% SDS-page gels or
NuPAGE

Novex 3–8% Tris-Acetate Protein Gels. Primary
antibodies are described above. Secondary antibodies were
purchased from Dako and signal detected using the enhanced
chemiluminescence (ECL, Amersham) western blot analysis
system.
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Identification of a p.E330K mutation
in CLCTL1 in a consanguineous,
painless family
We ascertained a consanguineous family of Balochi origin
after the birth of their second child—subsequently a third
affected child was born (Fig. 1A). All were unable to sense
pain from birth and were unresponsive to soft touch. By 3
months it was apparent that they were developmentally
delayed and in those 42 years it became clear that they
had severe, non-progressive learning difﬁculties. Motor
movements and strength were normal and hot and cold
could be perceived. Thus the phenotype was novel and dis-
tinct from known causes of Mendelian congenital painless-
ness such as hereditary sensory and autonomic neuropathy
type IV or V (Rotthier et al., 2012). For further clinical
details, see the online Supplementary material.
To ﬁnd the causative gene mutation, autozygosity map-
ping was performed and the results analysed on the as-
sumption of autosomal recessive inheritance. Using
Affymetrix SNP chips we delineated ﬁve shared homozy-
gous and concordant regions in the affected family mem-
bers—comprising a total of 49 cM (1.5% of genome).
Exome analysis was performed on one affected child and
analysis targeted to the ﬁve regions identiﬁed. Only one
Figure 1 Discovery of a CLTCL1 mutation in individuals with lack of pain or touch sensing and severe intellectual disability. (A)
Image of an affected child aged 5 years, noting corneal opacity secondary to lack of a corneal reflex. (B) Family pedigree with parents being double
first cousins and the filled in symbols indicating their affected children (two female and one male). (C) The affected individuals were concordant
and homozygous for consecutive variants in five autosomal regions. The candidate mutation was localized to one of these regions on chromosome
22. This contained the gene CLTCL1 for which a cartoon of the exon/intron structure is shown. In exon 7 we identified the c.988G4A mutation in
CLTCL1, for which electrophoretograms of the Sanger sequencing results are shown for an affected child homozygous for the mutant A allele, an
unaffected carrier parent heterozygous for the wild-type G and mutant A alleles, and a typical control wild-type G allele. The gene mutation
resulted in the alteration of an invariant negatively charged glutamic acid 330 to a basic charged lysine in the encoded protein CHC22. The amino
acid at position 330 in CHC22 is the first of an invariant pair of acidic amino acids present in all clathrin heavy chain proteins, which is
evolutionarily conserved through vertebrates (with two clathrin heavy chains, CHC17 and CHC22, termed 1 and 2, respectively in this figure),
insects and amoeba (with a single CHC17 like clathrin heavy chain). Protein sequence data are for human as a representative mammal (CHC22 is
NP_009029.3; CHC17 is NP_004850.1), Xenopus tropicalis for amphibians (XP_002931934.2; NP_001011039.1), Danio rerio for fish
(XP_005172491.1; XP_005157480.1), Gallus gallus for birds (Human Genome Browser, BLASTp and ACA13364.1; NP_001073586.1), Drosophila
melanogaster for flies (NP_477042.1), Caenorhabditis elegans as a nematode (NP_499260.1), and Dictyostelium discoideum, a slime mould, as an
amoeba (XP_642717.1). Upper case amino acid nomenclature is for invariance within a class, lowercase for amino acids that vary between species
of the class.
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candidate mutation was identiﬁed, c.988G4A in
CLTCL1, which was homozygous, previously unidentiﬁed,
and potentially pathogenic (Fig. 1C and Supplementary ma-
terial). The CLTCL1 mutation segregated in the family as
expected for an autosomal recessive, with all three affected
individuals homozygous for the mutation, the parents both
heterozygous and the one unaffected sibling available for
analysis, also heterozygous. Furthermore, we did not ﬁnd
the mutation in 360 control chromosomes or in the 1000
Genomes project (2012). We found no other potentially
pathogenic, concordant, homozygous or biallelic mutations
in the affected children.
CLTCL1 encodes the minor clathrin heavy chain
(CHC22), a relatively understudied protein proposed to
be involved in intracellular endosome trafﬁcking
(Vassilopoulos et al., 2009). The common clathrin heavy
chain (CHC17) is encoded by the gene CLTC on chromo-
some 17. CHC17 is expressed at a far higher level than
CHC22 and is present ubiquitously in all cell types; how-
ever, the pattern of CHC22 expression differs between tis-
sues and during development (Kedra et al., 1996;
Vassilopoulos et al., 2009). The mutation identiﬁed in
CLTCL1 leads to the substitution of an invariant glutamic
acid to a lysine, p.E330K, which is positioned at the
C-terminus of the seven bladed WD repeat containing
b-propeller that forms the adaptor binding domain of the
clathrin heavy chains. Position 330–331 in the clathrin
heavy chain is occupied by a pair of amino acids with
negatively charged side chains (predominantly glutamic
acid, less often aspartic acid). This pair of amino acids is
invariant in both clathrin heavy chain proteins in all mam-
mals (with the exception of rodents that have no CLTCL1
gene), ﬁsh, amphibians, birds, and the phylogenies with




endocytosis at the cell membrane
To assess the functional signiﬁcance of the p.E330K muta-
tion, it was introduced into a previously reported, func-
tional N-terminal GFP-tagged CHC22 construct
(constructs i and ii) (Hood and Royle, 2009) (Fig. 2).
There was no difference in the steady state levels of
mutant CHC22 versus wild-type CHC22 when expressed
in HEK293 cells, nor did this affect the stability of CHC17
(Fig. 3A and B). Further, when produced in E. coli, we
found that the mutation did not affect folding of the cla-
thrinN-terminal b-propeller domain (Supplementary Fig. 1).
We sought to investigate CHC22 endocytic function using
the validated transferrin internalization assay. Transferrin
receptors are internalized upon binding exogenous ﬂuores-
cent tagged transferrin by CHC17-containing clathrin
coated vesicles (CCVs). Knockdown of CHC17 blocks
this process (Hood and Royle, 2009; Esk et al., 2010).
CHC22 has been shown to be able to substitute for
CHC17 function and mediate CCV-dependent transferrin
internalization, but only when expressed at high levels
(comparable to wild-type CHC17 expression levels) and in
the absence of endogenous CHC17 (Liu et al., 2001;
Towler et al., 2004; Hood and Royle, 2009; Esk et al.,
2010; Brodsky, 2012). We therefore used this assay to
test if this mutation affects CHC22 CCV function in vivo
using constructs either expressing wild-type or p.E330K
containing CHC22, while simultaneously knocking down
endogenous CHC17 (constructs v and vi; Fig. 2) (Royle
et al., 2005; Hood and Royle, 2009). We veriﬁed our meth-
odology by showing signiﬁcant reduction in the uptake of
ﬂuorescent transferrin in cells treated with CHC17 shRNA
compared to GFP control cells (transfection with constructs
iii and iv; Fig. 3B and C). Constructs v and vi were trans-
fected into HEK293 cells to produce cells lacking CHC17
and expressing GFP-tagged CHC22 (Fig. 3B). In these
CHC17-deﬁcient cells, over-expression of CHC22.WT was
sufﬁcient to induce signiﬁcant transferrin endocytosis.
However, the mutant CHC22.E330K was unable to
rescue the deﬁciency of CHC17 (Fig. 3B and D). This was
also reﬂected in reduced co-localization between mutant
CHC22.E330K and transferrin compared with the wild-
type construct (Fig. 3E). These data demonstrate that the
p.E330K mutation disrupts the ability of CHC22 to rescue
clathrin-mediated endocytosis, thus suggesting that the
p.E330K is a pathogenic mutation.
CLTCL1 is highly expressed in the
developing human brain and is
downregulated in the postnatal
cortex
The expression of CLTCL1 compared to that of CLTC is
quite modest, with skeletal muscle displaying the highest
expression of any tissue tested to date (Vassilopoulos
et al., 2009). We hypothesized that if CLTCL1 were to
play a neurodevelopmental role, its expression pattern
might reveal an upregulation in the developing human
brain. To address this question, we analysed transcriptional
data previously published as part of the Developmental
Transcriptome published by the Allen Institute (http://brain-
span.org/). The gene expression data for both CLTC and
CLTCL1 were downloaded and analysed for the periods
spanning from embryonic (9 weeks post-conception) until
adult (40 years old). We identiﬁed that throughout all re-
gions of the cortex analysed, CLTCL1 displayed a peak of
expression between 12 and 13 weeks post-conception,
which then dropped between 4 - and 7-fold by early child-
hood (Fig. 4A). However, the expression of CLTC was
consistent throughout prenatal brain development and at
no developmental stage was up- or downregulated by
430% (likely indicating experimental variability, or vari-
ance between test subjects) (Fig. 4B). The hippocampus and
striatum also displayed increased CLTCL1 expression
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prenatally although peaking later in prenatal development
(Weeks 17–21), also a less marked reduction of expression
after birth (Fig. 4A). The thalamus and cerebellum did not
show signiﬁcantly increased CLTCL1 expression prenatally
(data not shown).
Next we transformed the relative expression data to de-
termine the comparative expression levels of CLTCL1 and
CLTC during brain cortex development. The percentage of
clathrin heavy chain represented by CLTCL1 in the de-
veloping prenatal cortex was between 5 and 5.7% on aver-
age (Q1 4.3–4.6%, Q3 5.5–6.7%). After birth, this value
signiﬁcantly dropped to between 2.8 and 3.0% total cla-
thrin heavy chain expression represented by CLTCL1 (Q1
1.7–2.1%, Q3 3.1–3.6%) (Fig. 4B).
CHC22 is downregulated in the
progression from neural crest to
sensory neuron-like in the
development of a pain neuron
The phenotype of affected children harbouring the
CLTCL1 mutation indicates both a central and peripheral
nervous system defect. Having found CLTCL1 to be ex-
pressed at an increased level in the prenatal cortex and to
show an expression proﬁle suggestive of a neurodevelop-
mental role, we sought to deﬁne a possible role for CHC22
during neurogenesis. To achieve this we investigated the
expression proﬁle of CHC22 during peripheral nervous
Figure 2 DNA plasmid constructs used in this study. (A) The eight constructs used in this study, colour coded for each feature. (B)
Summary of the effects of transfection of each construct (i–viii) on CHC17 and CHC22 level.
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system development in culture. Both pain and touch sensing
neurons originate from neural crest precursor cells (Liu and
Ma, 2011). Pain sensing nociceptors predominantly express
the transmembrane receptor TRKA (encoded by NTRK1),
which is activated by the neurotrophin NGFb (encoded by
NGF) during development to induce differentiation to a
post-mitotic nociceptor. Touch sensing neuron development
is similarly dependent upon activation of transmembrane
TRKB (encoded by NTRK2) by the neurotrophin BDNF
(Chao, 2003; Marmigere and Ernfors, 2007). Therefore,
we studied: human induced pluripotent stem cells differen-
tiated into pain neurons with small molecule inductors and
NGFb (Chambers et al., 2012); and human SH-SY5Y cells,
which are neural crest derived and differentiate into neural
cells following exposure to all-trans retinoic acid and
BDNF (Kaplan et al., 1993). The differentiation of these
cells progresses from a stem-cell like morphology, to a mi-
totic cell exhibiting signiﬁcant neurite outgrowth, and ﬁ-
nally to a post-mitotic neuronal cell (Fig. 5A and B). In
both systems induction of neuronal differentiation and
Figure 3 p.E330K in CLTCL1 is a pathogenic mutation. (A) The p.E330K mutation has no effect on the steady state levels of CHC22 or
CHC17 in HEK293 cells determined by western blotting. (B) Transferrin internalization assay was used to determine the functionality of the
p.E330K mutant in HEK293 cells. Red signal represents transferrin-Alexa Fluor

546, green indicates GFP or CHC22.GFP, and blue DAPI. (C)
Cells transfected with control shRNA and tagged with GFP (construct iii) display normal transferrin internalization, whereas transfection with
shRNA against CHC17 (construct iv) significantly inhibited transferrin internalization (P5 0.001). (D) Cells transfected with the same shRNA
construct against CHC17 also expressing wild-type CHC22 (construct v) displayed functional transferrin internalization, whereas cells transfected
with the same construct except carrying the p.E330K mutation (construct vi) demonstrated no rescue of transferrin internalization (P5 0.001
compared with pBrain.CHC22.WT). (E) There was also a reduced co-localization of CHC22.E330K (construct vi) with fluorescent transferrin
compared with CHC22.WT (construct v) tested by Pearson Co-localization Coefficient (P5 0.005). (C) Represents the pooled data from two
independent repeats confirming the previously demonstrated effect of CHC17 knock down on transferrin internalization (Esk et al., 2010; Willox
and Royle, 2012). At least 58 cells counted for each transfection condition. (D) Represents the pooled data from four independent experiments
normalized to pBrain.CHC22.WT. At least 136 cells counted for each transfection. (E) Represents pooled data from three independent ex-
periments. Statistical tests were two-tailed Student’s t-tests. Error bars represent standard error. For explanation of the constructs used in
greater detail, see Fig. 2.
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Figure 4 CLTCL1 is highly expressed in the developing human cortex. Heat maps demonstrating the expression profiles of CLTCL1 (A)
and CLTC (B), respectively, throughout development of various regions of the human brain. Note the increased expression of CLTCL1 during early
prenatal development and a drop after birth contrasting with the more linear expression profile for CLTC. The colours of the heat map are
expression values, transformed to a log2 scale and calculated as a percentage of the highest expression time point for each brain region,
respectively. The colour scale ranges from dark blue representing low expression through yellow to dark red representing high expression. The
key below demonstrates the colours assigned to each percentage expression. Blank boxes represent where no data were available. (B) Graphs
comparing the percentage of clathrin heavy chain expression (CLTC and CLTCL1) represented by CLTCL1 in various regions of the cortex. All
regions show a significant downregulation in the proportion of clathrin expression attributed to CLTCL1 after birth. On average CLTCL1 was
between and 6% of total clathrin before birth and 3% after birth. Horizontal bars represent the mean and error bars, the standard error.
Significance tests were Student’s t-test. Three stars represent P5 0.0001.
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neurite outgrowth was accompanied by a signiﬁcant down-
regulation of CHC22 protein levels (Fig. 5C and D).
CHC22 downregulation drives
neurite outgrowth
To test if the fall in CHC22 levels was involved in inducing
neural crest cell differentiation or was a consequence of it,
we designed two siRNAs against CLTCL1, both of which
we conﬁrmed to induce signiﬁcant downregulation of
CHC22 protein levels at Day 5 (Fig. 6A). SH-SY5Y cells
treated with either siRNA against CLTCL1 displayed a
dramatic change in cellular morphology with a more neur-
onal phenotype characterized by signiﬁcantly increased
neurite length per cell and percentage of cells bearing a
neurite (deﬁned as greater than twice the cell body
length) (Fig. 6B–D). We conﬁrmed that the effects on neur-
ite outgrowth were due to CHC22 knockdown and not off-
target effects by rescuing these effects by over expression of
CHC22 in SH-SY5Y cells. A CHC22 wild-type construct
was made resistant to siCHC22.2 (construct vii, Fig. 2) by
site-directed mutagenesis and stably introduced into SH-
SY5Y cells. Treatment of these cells with siRNA against
endogenous CLTCL1 failed to induce signiﬁcant neurite
outgrowth indicating rescue of the knockdown induced
phenotype (Fig. 6F and G).
In SH-SY5Y cells, differentiation with retinoic acid is
accompanied by an upregulation of TRKB that is essential
for induction of differentiation (Fig. 5C and 6E) (Esposito
et al., 2008). Therefore, we assessed whether CHC22 was
Figure 5 CHC22 is downregulated upon differentiation from a neural crest type cell to a sensory neuron-like cell. (A) Schematic
representation of the differentiation of human induced pluripotent stem cells differentiated into pain neurons with small molecule inductors and
NGFb and the differentiation of SH-SY5Y neural crest derived neuroblastoma cells with all-trans retinoic acid (RA) and BDNF. (B) Representative
phase contrast image of SH-SY5Y cells treated with retinoic acid or control DMSO (dimethyl sulphoxide) for 5 days; note the appearance of long
neurites extending from the cell body in the retinoic acid treated cells. (C) CHC22 is significantly downregulated upon treatment with retinoic
acid, whereas TRKB shows a significant upregulation under the same conditions. (D) CHC22 is downregulated across Days 5–7 of pain neuron
differentiation from human pluripotent stem cells, occurring at the transition of neural crest to sensory neuron cells and induction of neurite
outgrowth. For full time course, see Supplementary Fig. 3.
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involved in the vesicular trafﬁcking of TRKB in differentiat-
ing SH-SY5Y cells and found no evidence of this.
Furthermore, while treatment with retinoic acid caused a
reduction in CHC22 accompanied by TRKB upregulation,
knockdown of CLTCL1 induced a similar morphological
phenotype but with no change in TRKB levels. This indi-
cates that CHC22 loss induces differentiation in a TRKB-
independent manner (Fig. 6E).
p.E330K renders CHC22 unable to
negatively regulate neurite
outgrowth
Next, we sought to conﬁrm pathogenicity of the p.E330K
mutation by testing whether it affected the function of
CHC22 in neuronal differentiation. We manufactured a
construct bearing the familial CHC22 mutation that was
resistant to knockdown (construct viii; Fig. 2) and again
made stable SH-SY5Y cell lines. In these cells, despite ex-
pression of CHC22.E330K, knockdown of endogenous
CHC22 induced neurite outgrowth, indistinguishable from
the effects observed in untransfected parental cells (Fig. 6F
and G). These data further conﬁrm the induction of neurite
outgrowth to be a CHC22-speciﬁc effect, that CHC22 is an
essential negative regulator of sensory neuron differenti-
ation, and that the p.E330K mutation renders CHC22
unable to function in this process.
CHC22 downregulation is an
essential aspect of retinoic
acid-mediated differentiation
Having demonstrated that CHC22 overexpression could
rescue the differentiation phenotype associated with
siRNA-mediated knockdown of CHC22, we proceeded to
investigate if downregulation of CHC22 was essential for
differentiation by retinoic acid treatment. We took SH-
SY5Y cells stably overexpressing CHC22 WT.GFP or
CHC22 p.Glu330Lys.GFP and parental cells as a control,
and treated them with 10mM retinoic acid for 5 days.
After 5 days we imaged the cells (Fig. 6A) and quantiﬁed
neurite outgrowth. Although parental cells showed a signiﬁ-
cant increase in both the percentage of cells bearing a neurite
greater than two cell bodies in length, and in the total neur-
ite length per cell, cells expressing wild-type CHC22 were
resistant to neurite outgrowth induction by retinoic acid
(Fig. 7B and C). As expected, cells expressing the CHC22
mutant protein remained able to undergo differentiation, in
similar proportion to that of parental cells (Fig. 7B and C).
Discussion
We report the ﬁrst cases of a novel syndrome of absent
pain and touch sensing with cognitive delay. Genetic map-
ping and exome sequencing identiﬁed the potential
causative mutation to reside in the CLTCL1 gene encoding
CHC22, the second clathrin heavy chain protein. The
common clathrin heavy chain, CHC17 is ubiquitously ex-
pressed, whereas CHC22 displays a more restricted expres-
sion pattern. The functional unit of clathrin, known as a
triskelion, is composed of three trimerized heavy chain sub-
units and three light chain subunits. Triskelia self-assemble
on membranes forming a regular, polyhedral lattice asso-
ciated with the formation of endosomes (Brodsky, 2012).
The CHC17 protein functions in numerous endosomal traf-
ﬁcking pathways including receptor-mediated endocytosis
and endosomal sorting at the trans-golgi network.
However, the role of CHC22 is less well established but
has been demonstrated to have a non-redundant role in the
intracellular trafﬁcking of the GLUT4 glucose transporter
(encoded by SLC2A4) in postnatal muscle and fat tissue
(Vassilopoulos et al., 2009). Despite signiﬁcant structural
similarity, CHC22 and CHC17 seem to functional similarly
only when CHC22 is expressed at higher than physio-
logical levels (Esk et al., 2010). Here we identify an add-
itional, non-redundant role for CHC22 in the development
of nociceptive and mechanoreceptive neurons.
We found our family’s mutation to be pathogenic in an
in vitro assay of receptor-mediated endocytosis at the cell
membrane, albeit at non-physiological levels where
CHC22.WT or CHC22.E330K were overexpressed by trans-
fection and with CHC17 simultaneously knocked down. In
the presence of CHC22 at physiological levels and absence
of CHC17, transferrin internalization is blocked thus con-
ﬁrming that CHC22 alone cannot induce clathrin-mediated
endocytosis in HEK293 cells. We therefore propose that
CHC22 is likely to possess a distinct function to that of
CHC17 when expressed at normal cellular levels.
Previous studies have shown that CHC17 is much more
abundant than CHC22, and that after birth CHC22 is ex-
pressed at higher levels in muscle cells where it functions in
a cell-speciﬁc role in the formation of the GLUT4 storage
compartment (Vassilopoulos et al., 2009). We hypothesized
that were CHC22 to also play a cell-speciﬁc role in neuro-
genesis, it would also likely be expressed at higher levels in
the developing brain and that its expression pattern might
mimic that of other known neurodevelopmental genes
showing increase until mid-foetal development, and then
gradual decline with age until early childhood (Kang
et al., 2011; Tebbenkamp et al., 2014). Re-analysing data
from the ‘Brainspan Atlas of the Developing Human Brain’,
we found that in all regions of the cortex tested and in the
hippocampus and striatum, CLTCL1 was signiﬁcantly
increased during early prenatal development, dropping by
as much as 7-fold by early childhood. This was in contrast
to the expression of CLTC whose level is maintained
throughout the course of neurodevelopment. This gene ex-
pression trajectory strongly suggests that CHC22 functions
in neurodevelopment, potentially affecting neural progeni-
tors or immature neurons which are known to develop at
the time of peak CLTCL1 expression (Tebbenkamp et al.,
2014).
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To our surprise we found that during the development of
human neural crest-derived cell systems for TRKA/pain and
TRKB/touch neuron production, CHC22 is downregulated,
and that downregulation of CHC22 by siRNA actively in-
duces the differentiation of neural precursors. The inability
to induce this effect in cells stably expressing CHC22 dem-
onstrates that CHC22 has to be lost for development to
progress. In contrast, persistent expression of mutant
CHC22 was unable to rescue knockdown of endogenous
CHC22 in this process, thus further conﬁrming
pathogenicity of the p.E330K mutation in CLTCL1 and
suggesting the pathogenic mechanism for the mutation in
our family. We conclude that CHC22 is an essential nega-
tive regulator for the subset of neural crest progenitors that
produce pain and touch sensing neurons.
CLTCL1 derived from a duplication of CLTC coincident
with the emergence of vertebrates, an animal subphylum
deﬁned by the possession of a spinal column and neural
crest (Wakeham et al., 2005). Notwithstanding selective
pressures on CHC22 due to its function in postnatal,
Figure 6 Knockdown of CLTCL1 causes induction of neurite outgrowth. (A) Western blot demonstrating knockdown of CHC22 using
two separate siRNAs. Images taken on Day 5, SH-SY5Y cells having been treated with 15 nM siRNA on Days 1 and 4. (B) Representative Day 5
images of cells treated with indicated siRNAs. Cells treated with siRNA against CHC22 show significant neurite outgrowth. (C) Quantification of
average neurite length per cell and (D) percentage of cells bearing a neurite (at least twice the cell body length), pooled from six independent
repeats of the experiment with at least 1500 cells counted for each condition. (E) Western blot of SH-SY5Y cells differentiated by 5-day retinoic
acid treatment or transfection with CHC22 siRNA, both experiments lysed at Day 5. There is an upregulation of TRKB in the retinoic acid treated
cells, which is not apparent in the siCHC22 treated cells. (F) No significant increase in neurite length per cell or (G) percentage of cells bearing
neurites in SH-SY5Y cells overexpressing a siRNA resistant CHC22.WT GFP upon knockdown of endogenous CHC22. In p.E330K expressing
cells there is a significant increase in both the neurite length and percentage of cells bearing a neurite in cells overexpressing CHC22.E330K, upon
knockdown of endogenous CHC22. Statistical tests were two-tailed Student’s t-tests: *P5 0.05, **P5 0.01, ***P5 0.0001. Error bars represent
standard error. N.S = not significant.
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vertebrate muscle cells, it is conceivable that during devel-
opment, the original clathrin heavy chain might maintain a
generalized endosomal function but the duplicated clathrin
heavy chain adopt a role restricted to the newly emerged
vertebrate nervous system. We have not investigated the
speciﬁc cerebral cause of the cognitive disability in this
family, but note that CHC22 has been previously linked
to cerebral behavioural phenotypes (Chahrour et al., 2012).
There are two corollaries from our studies. Firstly, ro-
dents have lost CLTCL1 and thus must have alternative
pathway(s) to compensate for this. Thus, some pain re-
search results generated in these animals may not be ap-
plicable to man. Secondly, new classes of analgesics have
resulted from studying known Mendelian causes of pain-
lessness e.g. the developmental genes NTRK1 and NGF
(Holmes, 2012)—hopefully, similar advances will emerge
from the further study of CHC22 and the developmental
pathway it controls.
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Figure 7 Downregulation of CHC22 is essential for retinoic acid-mediated differentiation. (A) Representative images taken on Day
5 with or without treatment with 10mM retinoic acid (RA). Addition of retinoic acid to parental cells results in significant neurite outgrowth,
whereas stable expression of CHC22.WT.GFP blocked this process. Note white arrows indicating non-transfected cells undergoing differenti-
ation, but no evidence in cells expressing GFP. Stable expression of CHC22.E330K.GFP in SH-SY5Y cells are still able to be differentiated by
addition of retinoic acid. Note white arrows indicating differentiated cells which do express GFP. (B) Quantification of percentage of cells bearing
a neurite (greater than two cell bodies in length). (C) Quantification of the average neurite length per cell under each experimental condition.
Data represents at least three independent experiments. Statistical tests were Student’s t-test: *P5 0.05 and **P5 0.01. Error bars represent
standard error.
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